News
-
-
-
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
At CES 2025, METAVISIO - THOMSON Computing signed an agreement with ARC Group Limited for a listing on Nasdaq or NYSE, based on a minimum indicative valuation estimated at USD 70M (derived from audited annual data for FY2023 and audited data for H1-2024)
METAVISIO partners with ARC Group for listing on Nasdaq or NYSE, targeting $70M valuation. ARC to provide financial guidance for De-SPAC, RTO, or IPO. METAVISIO aims to expand global presence leveraging U.S. financial markets -
COMMUNIQUÉ DE PRESSE
Heidelberg Pharma Progresses into Cohort 7 in a Phase I/IIa Study with BCMA ATAC Candidate HDP-101 Targeting Multiple Myeloma
Heidelberg Pharma advances into Cohort 7 with BCMA ATAC candidate HDP-101 targeting multiple myeloma, showing promising results and complete remission in Phase I/IIa study
